Key facts
- Alphyn’s last known valuation is $83.0M (Dec 2025).
- It has raised $34.0M; the latest was Later Stage VC ($25.0M) in Dec 2025.
- Notable investors include Angel Physicians Fund, Angel Star Ventures, Opus8, Queen City Angels, Serial Stage Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Alphyn
- ·The full record, as it builds
Funding rounds
No funding rounds for Alphyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alphyn
Developer of therapeutics for severe and prevalent skin diseases designed for multiple bioactive therapeutic drugs. The company's lead candidate for atopic dermatitis (AD) to treat the bacterial cause and exacerbation of the disease, in addition to directly treating itch, inflammation, and infection that make AD so difficult to manage, it is also advancing a candidate for epidermolysis bullosa, enabling patients with a safe and effective cure for bacterial skin infections.
- Sector
- Healthcare
- HQ
- Annapolis, MD, United States
- Founded
- 2019
- Employees
- 4
- Website
- alphynbiologics.com/
- Ownership
- Privately Held (backing)
Alphyn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alphyn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alphyn in its N-PORT filings yet. We sweep new filings monthly.